Thinly traded micro cap Tyme Technologies (TYME +15.8%) is up on modestly higher volume on the heels of its announcement that preliminary data from a Phase 2 clinical trial evaluating lead candidate SM-88 in patients with pancreatic cancer will be presented at the Gastrointestinal Cancers Symposium in San Francisco on January 18, 2019.
Results from an earlier 10-subject study in treatment-resistant pancreatic cancer showed a 30% response rate.
SM-88 is a combination therapy that uses a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down their defenses and making them vulnerable to oxidative stress and death.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.